{"id":"tamoxifen-citrate-tamoxifen","safety":{"commonSideEffects":[{"rate":"25-40","effect":"Hot flashes"},{"rate":"20-30","effect":"Vaginal discharge"},{"rate":"15-25","effect":"Nausea"},{"rate":"1-3","effect":"Venous thromboembolism (DVT/PE)"},{"rate":"0.5-1","effect":"Endometrial cancer"},{"rate":"10-20","effect":"Vaginal bleeding"},{"rate":"10-20","effect":"Fatigue"},{"rate":"5-15","effect":"Mood changes/depression"}]},"_chembl":null,"_dailymed":{"setId":"8c0eb763-420a-4106-ba56-526b53a7f72b","title":"TAMOXIFEN CITRATE TABLET [BRYANT RANCH PREPACK]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tamoxifen competitively binds to estrogen receptors (ER) on hormone-responsive breast cancer cells, preventing endogenous estrogen from activating these receptors and promoting cell proliferation. In estrogen receptor-positive breast cancers, this blockade halts cell division and can induce apoptosis. Tamoxifen also has partial agonist activity in some tissues, which accounts for its effects on bone density and thromboembolic risk.","oneSentence":"Tamoxifen is a selective estrogen receptor modulator (SERM) that blocks estrogen binding to its receptor on breast cancer cells, inhibiting their growth.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:49:03.205Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive (HR+) breast cancer, adjuvant treatment"},{"name":"Metastatic breast cancer, HR+"},{"name":"Breast cancer risk reduction in high-risk women"},{"name":"Ductal carcinoma in situ (DCIS)"}]},"trialDetails":[{"nctId":"NCT05941520","phase":"PHASE2","title":"Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-08-23","conditions":"Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ","enrollment":80},{"nctId":"NCT06184750","phase":"PHASE2","title":"Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-27","conditions":"Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma","enrollment":200},{"nctId":"NCT07485569","phase":"PHASE1","title":"Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial","status":"NOT_YET_RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2026-06-01","conditions":"Thyroid Cancer Stage IV, Anaplastic Thyroid Cancer, Differentiated Thyroid Cancer","enrollment":10},{"nctId":"NCT02311933","phase":"PHASE2","title":"Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-05-28","conditions":"Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7","enrollment":81},{"nctId":"NCT06492616","phase":"PHASE3","title":"A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence","status":"RECRUITING","sponsor":"Stemline Therapeutics, Inc.","startDate":"2024-09-27","conditions":"Breast Cancer","enrollment":4220},{"nctId":"NCT00003140","phase":"PHASE3","title":"Letrozole After Tamoxifen in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"1998-08-24","conditions":"Breast Cancer","enrollment":5187},{"nctId":"NCT00310180","phase":"PHASE3","title":"Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2006-04-07","conditions":"Breast Adenocarcinoma, Hormone Receptor Positive, Stage IA Breast Cancer AJCC v7","enrollment":10273},{"nctId":"NCT06195306","phase":"PHASE2","title":"Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-07-28","conditions":"Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ","enrollment":66},{"nctId":"NCT01272037","phase":"PHASE3","title":"Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-02-28","conditions":"Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma","enrollment":5018},{"nctId":"NCT07287098","phase":"PHASE2","title":"A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-05","conditions":"Breast Neoplasms","enrollment":600},{"nctId":"NCT05467891","phase":"PHASE2","title":"Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"Oana Danciu","startDate":"2022-09-13","conditions":"Locoregional Recurrence, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":200},{"nctId":"NCT06944145","phase":"PHASE2","title":"New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia","status":"RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2025-12-03","conditions":"BPH (Benign Prostatic Hyperplasia), Lower Urinary Track Symptoms","enrollment":242},{"nctId":"NCT07483307","phase":"PHASE2","title":"A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-03-13","conditions":"Breast Cancer, HER2-negative Breast Cancer, HER2 Negative Breast Carcinoma","enrollment":176},{"nctId":"NCT07349069","phase":"PHASE3","title":"A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer","status":"RECRUITING","sponsor":"Shandong Suncadia Medicine Co., Ltd.","startDate":"2026-03-04","conditions":"Breast Cancer","enrollment":4800},{"nctId":"NCT05659563","phase":"PHASE2","title":"Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%","status":"COMPLETED","sponsor":"MedSIR","startDate":"2023-07-20","conditions":"Breast Cancer, Breast Cancer, Early-Onset","enrollment":92},{"nctId":"NCT03573648","phase":"PHASE2","title":"Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-11-13","conditions":"Breast Cancer","enrollment":33},{"nctId":"NCT00893061","phase":"PHASE3","title":"Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2009-03-16","conditions":"Breast Cancer","enrollment":44},{"nctId":"NCT06075953","phase":"PHASE2","title":"DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment","status":"RECRUITING","sponsor":"QuantumLeap Healthcare Collaborative","startDate":"2024-02-17","conditions":"Ductal Carcinoma in Situ","enrollment":400},{"nctId":"NCT07470606","phase":"PHASE2","title":"Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain","status":"NOT_YET_RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2026-03","conditions":"Brain Tumor","enrollment":108},{"nctId":"NCT06218303","phase":"PHASE1","title":"Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ","status":"RECRUITING","sponsor":"Finn, Olivera, PhD","startDate":"2024-02-07","conditions":"Ductal Carcinoma in Situ","enrollment":50},{"nctId":"NCT06982313","phase":"","title":"Long-term Follow-up of the TAM-01 Study and Pooled Analysis of Low-dose Tamoxifen Studies in Non-invasive or Microinvasive Breast Neoplasms","status":"COMPLETED","sponsor":"Ente Ospedaliero Ospedali Galliera","startDate":"1996-07-01","conditions":"Breast Cancer Invasive","enrollment":1545},{"nctId":"NCT06979596","phase":"PHASE2","title":"A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-08-11","conditions":"Malignant Neoplasm","enrollment":250},{"nctId":"NCT06671912","phase":"PHASE3","title":"Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial","status":"SUSPENDED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2025-02-19","conditions":"Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage 1 Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8","enrollment":1156},{"nctId":"NCT01788839","phase":"","title":"Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-02","conditions":"Breast Cancer, Lymphoma, Hodgkin's Lymphoma","enrollment":475},{"nctId":"NCT05894239","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-09-08","conditions":"Metastatic Breast Cancer","enrollment":230},{"nctId":"NCT07447024","phase":"NA","title":"Selected Exercise Program on Upper Cross Syndrome Post-unilateral Mastectomy","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2026-03-02","conditions":"Mastectomy","enrollment":60},{"nctId":"NCT04852887","phase":"PHASE3","title":"De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2021-06-07","conditions":"Stage I Breast Cancer","enrollment":1670},{"nctId":"NCT06434064","phase":"PHASE2","title":"Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-03-15","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Triple-Negative Breast Carcinoma","enrollment":30},{"nctId":"NCT06179303","phase":"PHASE2","title":"Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-07-22","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma","enrollment":60},{"nctId":"NCT06942039","phase":"EARLY_PHASE1","title":"Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation","status":"RECRUITING","sponsor":"C17 Council","startDate":"2025-09-23","conditions":"CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor","enrollment":15},{"nctId":"NCT05774951","phase":"PHASE3","title":"A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-03-31","conditions":"Breast Cancer, Early Breast Cancer","enrollment":4300},{"nctId":"NCT06507618","phase":"PHASE3","title":"Pre-Operative Window of ET to Inform RT Decisions (POWER II)","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2024-07-19","conditions":"Breast Cancer Female","enrollment":354},{"nctId":"NCT04059484","phase":"PHASE2","title":"Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2019-10-22","conditions":"Breast Cancer Metastatic","enrollment":367},{"nctId":"NCT04961996","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-08-27","conditions":"Early Breast Cancer","enrollment":4170},{"nctId":"NCT04024462","phase":"PHASE3","title":"A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-02-05","conditions":"HER2-positive Early Breast Cancer","enrollment":200},{"nctId":"NCT00003042","phase":"PHASE2","title":"Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"1997-05-30","conditions":"Breast Cancer","enrollment":41},{"nctId":"NCT06440967","phase":"PHASE3","title":"A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2024-07-31","conditions":"Hot Flashes","enrollment":540},{"nctId":"NCT06348134","phase":"PHASE2","title":"Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":"Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, HER2-positive Breast Cancer, Breast Cancer","enrollment":74},{"nctId":"NCT05101564","phase":"PHASE2","title":"Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer","status":"COMPLETED","sponsor":"Jennifer Lee Caswell-Jin","startDate":"2023-03-20","conditions":"Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer","enrollment":19},{"nctId":"NCT07071038","phase":"PHASE2","title":"Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients","status":"RECRUITING","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2025-10-17","conditions":"Breast Cancer, Adjuvant Treatment, Early Stage Breast Cancer","enrollment":62},{"nctId":"NCT02624973","phase":"PHASE2","title":"PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haukeland University Hospital","startDate":"2016-04-15","conditions":"Breast Cancer","enrollment":200},{"nctId":"NCT04504331","phase":"PHASE1","title":"Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer","status":"TERMINATED","sponsor":"Jennifer Lee Caswell-Jin","startDate":"2020-10-13","conditions":"Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer","enrollment":4},{"nctId":"NCT06585969","phase":"PHASE3","title":"A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"Danish Breast Cancer Cooperative Group","startDate":"2026-01-01","conditions":"Metastatic Breast Cancer, ER-positive Breast Cancer, Luminal B","enrollment":""},{"nctId":"NCT05878314","phase":"","title":"Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer","status":"RECRUITING","sponsor":"University Hospital Tuebingen","startDate":"2023-04-25","conditions":"Hormone Receptor Positive HER-2 Negative Breast Cancer","enrollment":504},{"nctId":"NCT01674140","phase":"PHASE3","title":"S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2013-09-12","conditions":"Breast Cancer","enrollment":1939},{"nctId":"NCT06917313","phase":"PHASE2","title":"FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy","status":"RECRUITING","sponsor":"Yale University","startDate":"2025-12-05","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3)","enrollment":92},{"nctId":"NCT00066703","phase":"PHASE3","title":"Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2003-11-03","conditions":"Breast Cancer","enrollment":2672},{"nctId":"NCT00066690","phase":"PHASE3","title":"Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2003-12-17","conditions":"Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma","enrollment":3066},{"nctId":"NCT02747004","phase":"PHASE2","title":"A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2016-09-14","conditions":"Metastatic Breast Cancer","enrollment":234},{"nctId":"NCT05161195","phase":"PHASE4","title":"Roll-over Study to Allow Continued Access to Ribociclib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-07-07","conditions":"Metastatic Breast Cancer","enrollment":134},{"nctId":"NCT05306340","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2022-08-03","conditions":"Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer","enrollment":373},{"nctId":"NCT05514054","phase":"PHASE3","title":"A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-10-04","conditions":"Breast Neoplasms","enrollment":8000},{"nctId":"NCT02057133","phase":"PHASE1","title":"A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2014-03-10","conditions":"Breast Neoplasms","enrollment":198},{"nctId":"NCT04570956","phase":"PHASE2","title":"Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia, Lobular Carcinoma In Situ, or Increased Breast Cancer Risk","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2021-07-26","conditions":"Breast Atypical Hyperplasia, Breast Lobular Carcinoma in Situ, Breast Atypical Lobular Hyperplasia","enrollment":65},{"nctId":"NCT03879577","phase":"PHASE2","title":"Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Chicago","startDate":"2019-11-25","conditions":"Breast Cancer, Breast Cancer Female, HER2-positive Breast Cancer","enrollment":53},{"nctId":"NCT07019363","phase":"PHASE3","title":"CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-06-15","conditions":"Breast Cancer, Adjuvant Therapy","enrollment":1903},{"nctId":"NCT02668666","phase":"PHASE2","title":"Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer","status":"COMPLETED","sponsor":"Oana Danciu, MD","startDate":"2017-02-01","conditions":"Hormone Receptor Positive Malignant Neoplasm of Breast, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Estrogen Receptor Positive Breast Cancer","enrollment":49},{"nctId":"NCT05296798","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-07-18","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":922},{"nctId":"NCT06001762","phase":"PHASE2","title":"TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2023-10-05","conditions":"Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma","enrollment":90},{"nctId":"NCT04584853","phase":"PHASE3","title":"PreOperative Endocrine Therapy for Individualised Care With Abemaciclib","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2020-12-23","conditions":"Breast Cancer Female","enrollment":123},{"nctId":"NCT05826964","phase":"PHASE2","title":"Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2023-06-12","conditions":"Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer","enrollment":24},{"nctId":"NCT04906395","phase":"PHASE3","title":"Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tolmar Inc.","startDate":"2021-07-01","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT05645536","phase":"PHASE3","title":"Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study","status":"ENROLLING_BY_INVITATION","sponsor":"Tolmar Inc.","startDate":"2022-12-28","conditions":"Breast Cancer","enrollment":250},{"nctId":"NCT05051722","phase":"","title":"Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2021-08-03","conditions":"Endometrial Cancer, Cervical Cancer, Atypical Endometrial Hyperplasia","enrollment":3110},{"nctId":"NCT05150652","phase":"PHASE2","title":"Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Irada Ibrahim-zada","startDate":"2022-02-18","conditions":"Breast Cancer, HER2-negative Breast Cancer, Node-negative Breast Cancer","enrollment":8},{"nctId":"NCT05501704","phase":"PHASE2","title":"ETHAN - ET for Male BC","status":"RECRUITING","sponsor":"Jose Pablo Leone","startDate":"2023-10-11","conditions":"Male Breast Cancer, Hormone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma","enrollment":60},{"nctId":"NCT06630325","phase":"PHASE2","title":"A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-06-24","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":30},{"nctId":"NCT01196936","phase":"PHASE2","title":"Low-Dose Tamoxifen Citrate in Reducing Breast Cancer Risk in Radiation-Induced Cancer Survivors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2010-09","conditions":"Breast Cancer","enrollment":84},{"nctId":"NCT05056857","phase":"","title":"Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-01","conditions":"Breast Carcinoma","enrollment":290},{"nctId":"NCT01273168","phase":"PHASE1","title":"Endoxifen in Adults With Hormone Receptor Positive Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-03-01","conditions":"Hormone Receptor-Positive Breast, Gynecologic, Desmoid","enrollment":40},{"nctId":"NCT05035836","phase":"PHASE2","title":"A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-11-16","conditions":"Breast Cancer, HER2-positive","enrollment":20},{"nctId":"NCT04174352","phase":"EARLY_PHASE1","title":"FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2020-10-20","conditions":"ERα+ Breast Cancer, ESR1 Gene Mutation","enrollment":12},{"nctId":"NCT07289035","phase":"PHASE2","title":"Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators.","status":"NOT_YET_RECRUITING","sponsor":"Azienda Ospedaliera Universitaria Integrata Verona","startDate":"2026-01-15","conditions":"Cystic Fibrosis - Complete","enrollment":35},{"nctId":"NCT06369285","phase":"PHASE2","title":"A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Puma Biotechnology, Inc.","startDate":"2024-11-19","conditions":"Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer, Recurrent Breast Cancer","enrollment":150},{"nctId":"NCT06660030","phase":"","title":"Factors Influencing Tamoxifen Adherence in Women With Breast Cancer Receiving Tamoxifen in Botswana.","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2024-03-01","conditions":"Breast Cancer Female","enrollment":10},{"nctId":"NCT02630693","phase":"PHASE2","title":"Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Canadian Cancer Trials Group","startDate":"2016-04-08","conditions":"Breast Cancer","enrollment":180},{"nctId":"NCT01771458","phase":"PHASE2","title":"A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer","status":"COMPLETED","sponsor":"Institut Curie","startDate":"2012-10","conditions":"Reccurent/Metastatic Solid Tumor Disease","enrollment":742},{"nctId":"NCT04733118","phase":"PHASE2","title":"Chemotherapy-Free pCR-Guided Strategy With Trastuzumab-pertuzumab and T-DM1 in HER2-positive Early Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"MedSIR","startDate":"2021-08-05","conditions":"Early Breast Cancer","enrollment":393},{"nctId":"NCT04565054","phase":"PHASE3","title":"Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"West German Study Group","startDate":"2020-09-02","conditions":"Breast Cancer Female","enrollment":1260},{"nctId":"NCT06364267","phase":"PHASE2","title":"Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.","status":"RECRUITING","sponsor":"Andrea DeCensi","startDate":"2025-10-01","conditions":"Breast Cancer","enrollment":140},{"nctId":"NCT02101788","phase":"PHASE2, PHASE3","title":"Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-04-11","conditions":"Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma, Ovarian Serous Adenocarcinoma","enrollment":260},{"nctId":"NCT04569747","phase":"PHASE2","title":"A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2021-01-11","conditions":"HER2-positive Breast Cancer, Invasive Carcinoma of the Breast, Breast Cancer","enrollment":375},{"nctId":"NCT03280563","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-12-22","conditions":"Breast Neoplasms","enrollment":144},{"nctId":"NCT03707340","phase":"PHASE2","title":"A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-09-14","conditions":"Breast Cancer, Hyposexual Desire Disorder","enrollment":43},{"nctId":"NCT05607004","phase":"PHASE2","title":"(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"Atossa Therapeutics, Inc.","startDate":"2023-02-14","conditions":"Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer","enrollment":87},{"nctId":"NCT04272801","phase":"PHASE2","title":"Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shayna Showalter, MD","startDate":"2020-04-07","conditions":"Breast Cancer Female","enrollment":84},{"nctId":"NCT06361940","phase":"PHASE2","title":"Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2024-09-30","conditions":"Breast Cancer","enrollment":100},{"nctId":"NCT04009044","phase":"PHASE2","title":"Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2020-02-17","conditions":"Cancer Survivor, Ductal Breast Carcinoma In Situ, Invasive Breast Carcinoma","enrollment":156},{"nctId":"NCT07213206","phase":"PHASE3","title":"CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-10-07","conditions":"Breast Cancer","enrollment":1500},{"nctId":"NCT06449027","phase":"PHASE3","title":"Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2024-08-21","conditions":"Breast Cancer Subjects","enrollment":211},{"nctId":"NCT07190443","phase":"PHASE3","title":"Adjuvant Abemaciclib for Locoregional Recurrence of HR-positive, HER2-negative Breast Cancer (JCOG2313, AURA)","status":"RECRUITING","sponsor":"Japanese Foundation for Cancer Research","startDate":"2025-02-07","conditions":"Breast Cancer, Locoregional Recurrence, Abemaciclib","enrollment":290},{"nctId":"NCT05128773","phase":"PHASE3","title":"Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity","status":"TERMINATED","sponsor":"Sanofi","startDate":"2022-02-17","conditions":"Breast Cancer","enrollment":3},{"nctId":"NCT07145827","phase":"NA","title":"Effect of Metformin on Endometrial Thickness in Postmenopausal Breast Cancer Patients Receiving Tamoxifen","status":"COMPLETED","sponsor":"Uruk University","startDate":"2024-01-02","conditions":"Breast Cancer, Endometrial Hyperplasia and Endometrial Cancers","enrollment":60},{"nctId":"NCT07153757","phase":"PHASE3","title":"De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-09-01","conditions":"Breast Cancer Early Stage Breast Cancer (Stage 1-3)","enrollment":2934},{"nctId":"NCT04134598","phase":"PHASE3","title":"ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2021-02-08","conditions":"Breast Cancer","enrollment":926},{"nctId":"NCT06033092","phase":"PHASE2","title":"Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Institute of Oncology","startDate":"2024-06-21","conditions":"BRCA Mutation, PALB2 Gene Mutation, Ductal Carcinoma in Situ","enrollment":200},{"nctId":"NCT05512364","phase":"PHASE3","title":"Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2023-12-15","conditions":"ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer","enrollment":220},{"nctId":"NCT07101159","phase":"PHASE2","title":"Dalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage Patients","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-09","conditions":"Early Breast Cancer, Adjuvant Therapy, Hormone Receptor Positive / HER2-negative Breast Cancer","enrollment":200},{"nctId":"NCT04300790","phase":"PHASE2","title":"Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients","status":"COMPLETED","sponsor":"MedSIR","startDate":"2020-10-23","conditions":"Breast Cancer","enrollment":69},{"nctId":"NCT02476786","phase":"PHASE2","title":"Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2017-01-17","conditions":"Breast Cancer, Cancer of Breast, Breast Neoplasms","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nolvadex","Tam","Tamoxifen"],"phase":"marketed","status":"active","brandName":"tamoxifen citrate (Tamoxifen)","genericName":"tamoxifen citrate (Tamoxifen)","companyName":"H. Lee Moffitt Cancer Center and Research Institute","companyId":"h-lee-moffitt-cancer-center-and-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tamoxifen is a selective estrogen receptor modulator (SERM) that blocks estrogen binding to its receptor on breast cancer cells, inhibiting their growth. Used for Hormone receptor-positive (HR+) breast cancer, adjuvant treatment, Metastatic breast cancer, HR+, Breast cancer risk reduction in high-risk women.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}